Global Health Analyst Review May 2026

This Global Health analyst review for May 2026 covers the key data investors need for MEDANTA at its current price of Rs 1,224.60. Global Health (NSE: MEDANTA) is the operator of Medanta hospitals, a leading multi-specialty hospital chain with a market capitalisation of approximately Rs 20,000 crore. The analyst consensus target of Rs 1,350 implies meaningful upside, and this Global Health analyst review examines technical levels, business performance, valuation, and key risks for MEDANTA through FY27.

Click Here – Get Free Investment Predictions

Global Health Company Snapshot May 2026

Medanta’s flagship Gurugram hospital and new hospitals in Lucknow, Patna, Ranchi, Noida, and Indore target the premium healthcare market. Cardiac sciences, oncology, and organ transplants are the clinical centres of excellence. The table below summarises the key data referenced in this Global Health analyst review.

Parameter	Value
NSE Ticker	MEDANTA
Sector	Healthcare – Multi-Specialty Hospitals
CMP (May 2026)	Rs 1,224.60
52 Week High	Rs 1,456.50
52 Week Low	Rs 956.00
Market Cap	Rs 20,000 Crore
Trailing P/E	55x
Analyst Consensus Target	Rs 1,350
Bull Case Target	Rs 1,650
Bear Case Target	Rs 900

Analyst Insight in This Global Health Analyst Review

Associate Director Kunal Singla suggests watching Global Health closely in May 2026. At Rs 1,224.60, Kunal Singla flags Healthcare – Multi-Specialty Hospitals sector dynamics as the primary driver for MEDANTA’s near-term price action. He notes support in the Rs 975 to Rs 1163 zone and flags any sustained close above Rs 1298 as a positive signal. Kunal Singla’s perspective adds professional analysis to this Global Health analyst review and is not a buy recommendation.

Technical Analysis in This Global Health Analyst Review

At Rs 1,224.60, MEDANTA is trading within its 52-week band of Rs 956.00 to Rs 1,456.50. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.

Near-term support is identified in the Rs 975 to Rs 1163 band while resistance is seen in the Rs 1298 to Rs 1287 zone. A sustained move above Rs 1298 could open the path toward the analyst consensus target of Rs 1,350 as identified in this Global Health analyst review.

Screen the best stocks on the Univest Screener.

Key Support and Resistance Levels

• Support Zone: Rs 975 to Rs 1163 – investors tracking this Global Health analyst review should watch for stabilisation or a bounce in this range as a potential accumulation signal for MEDANTA.
• Resistance Zone: Rs 1298 to Rs 1287 – a sustained close above Rs 1298 would be a positive breakout signal worth flagging in this Global Health analyst review.
• Medium-Term Target: The analyst consensus of Rs 1,350 represents the base-case upside scenario in this Global Health analyst review.

Business Segment Analysis

Multi-Specialty Hospitals (Medanta Brand)

This is the primary revenue and margin driver for Global Health, directly supporting the earnings trajectory toward the consensus target of Rs 1,350.

Cardiac Sciences and Organ Transplant Centres

This segment adds scale and diversification to Global Health’s business model and is a meaningful EPS contributor through FY27 and FY28.

New Hospital Expansion (Tier 1 and Tier 2 Cities)

This represents the medium-term growth frontier for Global Health and a key re-rating catalyst for the stock over the next 12 to 24 months.

Valuation in This Global Health Analyst Review

At Rs 1,224.60, Global Health trades at a trailing P/E of 55x. This Global Health analyst review presents three scenarios: a bull case of Rs 1,650 on strong earnings delivery, a base case of Rs 1,350 at analyst consensus, and a bear case of Rs 900 if macro headwinds persist. Q1 FY27 results will be the first key checkpoint for this Global Health analyst review.

Scenario	Target Price	Key Condition
Bull Case	Rs 1,650	Strong earnings delivery and sector re-rating
Base Case (Consensus)	Rs 1,350	Moderate growth, analyst consensus estimate
Bear Case	Rs 900	Earnings miss or macro headwinds

Trade Outlook for Global Health

Based on the technical and fundamental analysis in this Global Health analyst review, investors might watch MEDANTA near the support zone of Rs 975 to Rs 1163 for potential opportunities. A flag above Rs 1298 could suggest improving momentum toward Rs 1,350. This article uses watch-and-flag language only and does not constitute a trade recommendation.

Key Risks for Global Health in FY27

A well-rounded Global Health analyst review must assess downside risks. Key risks for Global Health include a macro slowdown affecting Healthcare – Multi-Specialty Hospitals sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in MEDANTA.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Conclusion: Global Health Analyst Review Verdict for 2026

This Global Health analyst review concludes that at Rs 1,224.60, MEDANTA offers a defined risk-reward with a consensus target of Rs 1,350. The 52-week range of Rs 956.00 to Rs 1,456.50 provides context on the current entry point. Use this Global Health analyst review as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on MEDANTA.

Frequently Asked Questions: Global Health Analyst Review 2026

What is the analyst target for Global Health in 2026?

The analyst consensus target is Rs 1,350, with a bull case of Rs 1,650 and a bear case of Rs 900. This Global Health analyst review recommends monitoring Q1 FY27 earnings for confirmation.

Is Global Health a good investment at Rs 1,224.60?

At Rs 1,224.60 with a P/E of 55x and a consensus target of Rs 1,350, this Global Health analyst review is constructive for medium to long-term investors in the Healthcare – Multi-Specialty Hospitals sector. Always consult a SEBI-registered advisor before investing.

What is Global Health’s 52-week high and low?

The 52-week high is Rs 1,456.50 and the 52-week low is Rs 956.00. At Rs 1,224.60, MEDANTA is positioned within this range as noted in this Global Health analyst review.

What are the key risks for Global Health?

Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the Healthcare – Multi-Specialty Hospitals sector as assessed in this Global Health analyst review.

Where can I track live data for Global Health?

Track Global Health’s live price and analyst targets on the Univest Screener alongside professional financial advice to complement this Global Health analyst review.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.